Daniel E Speiser Selected Research

EMD 521873

1/2013	T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein.
1/2013	A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel E Speiser Research Topics

Disease

119	Neoplasms (Cancer) 01/2022 - 01/2002
73	Melanoma (Melanoma, Malignant) 01/2021 - 01/2002
9	Neoplasm Metastasis (Metastasis) 01/2022 - 05/2004
7	Testicular Neoplasms (Testicular Cancer) 01/2019 - 02/2006
6	Infections 05/2022 - 02/2003
6	Communicable Diseases (Infectious Diseases) 01/2021 - 06/2005
5	Virus Diseases (Viral Diseases) 01/2021 - 01/2010
5	Inflammation (Inflammations) 01/2020 - 01/2015
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 01/2016
4	Persistent Infection 01/2019 - 05/2012
4	Colorectal Neoplasms (Colorectal Cancer) 11/2017 - 06/2007
3	Yellow Fever 01/2020 - 04/2015
3	Urinary Bladder Neoplasms (Bladder Cancer) 01/2020 - 02/2017
3	Colonic Neoplasms (Colon Cancer) 12/2015 - 11/2007
3	Human Influenza (Influenza) 08/2010 - 07/2004
2	Colitis 01/2019 - 11/2016
2	Non-Muscle Invasive Bladder Neoplasms 08/2017 - 02/2017
2	Multiple Myeloma 01/2014 - 02/2008
2	Squamous Cell Carcinoma of Head and Neck 02/2013 - 06/2011
1	Carcinoma (Carcinomatosis) 01/2022
1	Lung Neoplasms (Lung Cancer) 01/2021
1	COVID-19 07/2020
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2020
1	Carcinogenesis 01/2020
1	Wounds and Injuries (Trauma) 01/2020

Drug/Important Bio-Agent (IBA)

50	Peptides (Polypeptides)IBA 01/2022 - 01/2002
42	AntigensIBA 01/2022 - 02/2002
28	MART-1 AntigenIBA 01/2020 - 01/2002
26	VaccinesIBA 01/2022 - 10/2002
18	Neoplasm Antigens (Tumor Antigens)IBA 01/2022 - 01/2002
14	CytokinesIBA 01/2021 - 04/2005
13	Proteins (Proteins, Gene)FDA Link 01/2021 - 03/2007
10	LigandsIBA 01/2019 - 01/2010
9	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2016
9	Biomarkers (Surrogate Marker)IBA 01/2021 - 11/2016
8	HLA-A*02:01 antigenIBA 09/2014 - 02/2003
7	AntibodiesIBA 05/2022 - 10/2002
7	EpitopesIBA 01/2021 - 10/2003
6	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022 - 09/2008
6	incomplete Freund's adjuvantIBA 03/2016 - 10/2003
6	HLA-A2 Antigen (HLA A2 Antigen)IBA 01/2014 - 10/2002
5	IpilimumabIBA 10/2020 - 03/2014
5	Cancer VaccinesIBA 01/2019 - 09/2003
4	Interleukin-2 (IL2)IBA 01/2013 - 04/2005
4	AutoantigensIBA 01/2013 - 03/2008
3	InterferonsIBA 01/2021 - 10/2020
3	Granzymes (Granzyme)IBA 01/2021 - 03/2007
3	RNA (Ribonucleic Acid)IBA 01/2021 - 09/2015
3	NivolumabIBA 10/2020 - 01/2016
3	Blocking AntibodiesIBA 01/2020 - 01/2012
3	Indicators and Reagents (Reagents)IBA 01/2020 - 08/2010
3	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 01/2013
3	Biological ProductsIBA 01/2019 - 08/2013
3	Programmed Cell Death 1 ReceptorIBA 11/2018 - 06/2013
3	human soluble LAG-3 proteinIBA 03/2016 - 01/2011
3	Monoclonal AntibodiesIBA 05/2015 - 04/2005
3	OligodeoxyribonucleotidesIBA 03/2008 - 07/2006
3	Protein Subunit VaccinesIBA 04/2005 - 01/2002
2	Interleukin-6 (Interleukin 6)IBA 01/2021 - 08/2015
2	Neutralizing AntibodiesIBA 01/2021 - 07/2020
2	Adenosine (Adenocard)FDA LinkGeneric 01/2020 - 10/2019
2	pembrolizumabIBA 07/2019 - 11/2016
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2019 - 02/2013
2	Transcription Factors (Transcription Factor)IBA 01/2019 - 12/2008
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2019 - 10/2009
2	NanovaccinesIBA 01/2019 - 01/2019
2	Differentiation AntigensIBA 01/2019 - 02/2006
2	Messenger RNA (mRNA)IBA 11/2017 - 06/2011
2	Monatide (IMS 3015)IBA 03/2016 - 11/2012
2	Pharmaceutical PreparationsIBA 12/2014 - 05/2012
2	EMD 521873IBA 01/2013 - 01/2013
2	ProMune (CpG 7909)IBA 06/2012 - 03/2005
1	ChromatinIBA 01/2021
1	BO-112IBA 10/2020
1	Poly I-CIBA 10/2020
1	NucleotidesIBA 10/2020
1	Cell Surface ReceptorsIBA 01/2020
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2020
1	KynurenineIBA 01/2020
1	Chemokine CXCL10IBA 01/2020
1	beta-apocarotenoid-14',13'-dioxygenase (ADO)IBA 10/2019
1	Complement System Proteins (Complement)IBA 01/2019
1	Tetanus Toxoid (Vaccine, Tetanus)FDA Link 01/2019
1	Interleukin-10 (Interleukin 10)IBA 01/2019
1	Maf Transcription FactorsIBA 01/2019
1	Cre recombinaseIBA 01/2019
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2019
1	Immunoglobulin G (IgG)IBA 01/2019
1	CC ChemokinesIBA 01/2019
1	Glycoproteins (Glycoprotein)IBA 01/2019
1	MicroRNAs (MicroRNA)IBA 01/2019
1	Monophenol Monooxygenase (Tyrosinase)IBA 01/2019
1	Dinoprostone (PGE2)FDA Link 01/2019
1	Sialic Acid Binding Immunoglobulin-like LectinsIBA 11/2018

Therapy/Procedure

49	Immunotherapy 03/2021 - 01/2002
40	Therapeutics 12/2021 - 04/2005
5	Drug Therapy (Chemotherapy) 04/2014 - 03/2008
2	Cell- and Tissue-Based Therapy (Cell Therapy) 10/2020 - 05/2015
2	Injections 01/2019 - 02/2017
1	Lymph Node Excision (Lymph Node Dissection) 01/2019